Cancer Biomarkers Market Size Analysis:
The Cancer Biomarkers Market size was valued at USD 31.09 billion in 2024 and is expected to reach USD 72.64 billion by 2032, growing at a CAGR of 11.23% over the forecast period of 2025-2032.
The global cancer biomarkers market is growing due to the rising incidence of cancer, rapid technological advancements in diagnostic platforms, and the emergence of new diagnostic biomarkers. The rising demand for early disease diagnosis, targeted therapies, and personalized treatment has resulted in innovation in the field of biomarker discovery and validation. The introduction of genomics, proteomics, and bioinformatics is improving diagnostic precision.
The U.S. cancer biomarkers market size was valued at USD 9.96 billion in 2024 and is expected to reach USD 22.70 billion by 2032, growing at a CAGR of 10.88% over the forecast period of 2025-2032.
The North American cancer biomarkers market growth is led by the U.S. as a result of advanced healthcare infrastructures, extensive uptake of precision medicine, and a robust research and development sector. Dominance of the country in the area can be attributed to the availability and the presence of major biotechnology and pharmaceutical companies in the country, along with the favorable government programs to support cancer research.
Cancer Biomarkers Market Dynamics
Drivers
- Rising Burden of Cancer Cases Globally is Driving the Market Growth
The global incidence of cancer is continuing to grow, and millions of new cases are diagnosed annually. Factors including aging populations, a shift in lifestyle (such as more tobacco usage, poor diet, and sitting down), and environmental exposures are fuelling the rise. As cancer grows more prevalent, health systems are under pressure to identify it earlier and with greater precision. Cancer biomarkers can play a critical role in early diagnosis, leading to the best treatment outcome and a better survival rate. This rising requirement for early and accurate diagnosis of cancer is a key factor fueling the demand for biomarker-based tests among hospitals, diagnostic labs, and research institutes.
The World Health Organisation (IARC) estimated around 20 million new cancer cases and 9.7 million deaths worldwide in 2022 and predicted this would rise to 35 million new cases by 2050 due to population aging and current trends in exposure to risk factors such as obesity and pollution.
- Omics and Molecular Diagnostics are Progressing the Market Growth
Cancer biomarker discovery processes have been revolutionized by the rapid developments in genomics, proteomics, and transcriptomics (so-called "omics" technologies). Researchers are also able to assess the expression of genes, proteins, and RNA at the molecular level, in turn providing new, unique patterns for different types of cancer. Such discoveries have advanced the discovery of new ultra-specific biomarkers. Moreover, molecular tests as next-generation sequencing (NGS) and real-time PCR, are rapidly providing faster and more cost-effective results, leading them to become more commonly used in clinical practice. These improvements contribute to better diagnostic precision and spur personalized treatment regimens, further propelling market expansion.
Liquid biopsy blood tests for early detection of multiple cancers are showing that they can detect and validate 70% of cancer-related genetic markers up to three years before the traditional diagnosis of stage III or stage IV cancer, and major validation trials are ongoing that are now enrolling tens of thousands of people in the U.S.
Advances in NGS-based MRD detection (including Guardant Health’s and Exact Sciences' ctDNA assays) are making early relapse detection and patient monitoring possible long before recurrence is visible on imaging, thereby changing the paradigm of cancer care.
Artificial intelligence in immunohistochemistry and spatial proteomics is poised to unify biomarker interpretation in cancer.
Restraint
- The Cost of Biomarker Discovery and Validation is Hindering the Market Growth
One of the major challenges in the cancer biomarkers market analysis is the expensive process of discovery and validation of these biomarkers. It is lengthy and complex, beginning with upstream basic research that identifies candidate biomarkers, and continuing on through rigorous clinical validation by means of multi-stage trials to guarantee the accuracy, specificity, and dependability of the approach. It would be a heavy financial burden to establish a diagnostic tool or system that is compatible with genomic sequencing tools and bioinformatics systems. In addition, companies have to maneuver through often-treacherous regulatory landscapes that involve bulky trial documentation and rules to stringently adhere to (the FDA, EMA, etc.) These all contribute to the process being highly capital-intensive and therefore inhibit small players from participating in the creation of markets at their optimal pace.
Cancer Biomarkers Market Segmentation Insights
By Type
The breast cancer segment dominated the cancer biomarkers market share with 36.10% in 2024, attributed to the high prevalence of breast cancer across the globe, particularly in women, and rising initiatives from government and non-government organizations, and funding, are driving the market. Based on the fact that there are well-established biomarker tests including BRCA1/BRCA2, HER2, and hormone receptor markers, precision diagnostics and personalized therapies have gained momentum. Additionally, huge research and development and early screening expenditure, particularly in developed countries, have quickened the clinical applicability of biomarkers in the treatment of breast cancer, hence augmenting the dominance of the market segment.
The Others segment, which comprises carcinomas, leukemias, lymphomas, skin cancers, and central nervous system cancers, is expected to be the fastest-growing segment in the forecast period. Driving this surge is the increasing investment in and development of biomarkers for rare and aggressive cancers. In addition, multi-omics technologies and AI-driven platforms are increasing the number of biomarkers identified and validated in various cancer types. Additionally, the rising number of clinical trials and the extension of therapeutic applications beyond prevalent cancer types are also driving the growth of this market.
By Biomolecule
The genetic biomarkers segment dominated the cancer biomarkers market with 34.16% market share in 2024. Genetic alterations, such as BRCA1/2, KRAS, EGFR, and TP53, have been explored widely and are commonly implemented in the clinic for a variety of cancers, including breast, lung, and colorectal cancer. The dominance of this segment is highly attributed to the fact that genetic biomarker tests are accurate, reproducible in results, and have been largely accepted across many developed healthcare systems of the globe in personalized medicine. Furthermore, the incorporation of advanced technologies such as NGS has improved the sensitivity and the range of detected genetic aberrations.
The epigenetic biomarkers segment is anticipated to witness the highest CAGR in the forecast years on account of the growing awareness of epigenetic modifications such as DNA methylation, histone modification, and non-coding RNA expression as early-stage indicators of cancer. These biomarkers have good potential for non-invasive diagnosis of the disease and can be used for early disease detection and as a disease progression monitoring tool. Recent progress in the field of epigenomics and the increase in the number of epigenetic marker-based diagnostic tools would contribute to advancing epigenetic research and make it clinically relevant.
By Application
The HER-2 segment dominated the cancer biomarkers market in 2024, owing to the high demand for the diagnosis and treatment of HER2-positive breast cancer. HER-2 (Human Epidermal Growth Factor Receptor 2) is the most extensively validated prognostic and predictive biomarker, particularly in breast and gastric tumors. The emergence of targeted therapies, such as trastuzumab (Herceptin) and pertuzumab, and the underlying companion diagnostic tests, has significantly broadened their clinical application.
The EGFR market is expected to experience the fastest growth during the forecast period as it becomes increasingly relevant across a variety of cancer indications, including non-small cell lung cancer (NSCLC). EGFR (Epidermal Growth Factor Receptor) mutation detection is becoming more common with the use of advanced molecular diagnostic modalities, leading to the use of therapy with targeted agents (i.e., erlotinib, gefitinib, osimertinib). Growing recognition of EGFR’s involvement in cancer progression, progress in non-invasive/blood-based testing such as liquid biopsy, and growing research on EGFR inhibitors in other types of cancers are some of the factors driving EGFR biomarker testing’s explosive growth in the future.
By Technology
The diagnostics segment dominated the cancer biomarkers market with a 46.13% market share in 2024, attributed to the increasing use of biomarkers in drug development and discovery and the growing demand for personalized medicine in cancer therapies. Diagnostic biomarkers are now routinely incorporated into cancer-screening programs, especially those for breast, colorectal, and prostate cancer. High sensitivity and specificity provide accurate decisions in the clinic to improve the patient's prognosis, avoid invasive procedures. In addition, regulatory clearances and reimbursement for diagnostic assays based on biomarkers have tremendously added to their dominance in the market.
The personalized medicine segment is expected to exhibit the fastest growth throughout the forecast period due to the rising necessity of personalized therapeutics. Through personalized medicine and targeting of cancer biomarkers, optimal therapy can be based on one's genetic profile, resulting in maximum effect and minimal side effects. This trend has been further accelerated due to the many developments in NGS, the extended use of companion diagnostics, and the increase in biomarker studies across clinical trials.
Regional Outlook:
North America dominated the cancer biomarkers market with a 42.1% market share in 2024, as it has a developed healthcare system, large investment in cancer research, and high advancement of precision medicine. Such factors include a strong presence of major pharmaceutical and biotechnology companies in the region, high levels of funding from public and private sources, and high awareness among patients and healthcare professionals pertaining to early diagnosis of cancer. Additionally, the favorable regulatory ecosystem in nations such as the U.S. and Canada is conducive to the creation and distribution of advanced diagnostic and therapeutic tools based on biomarkers, which further assists the region in solidifying its position in the market.
Asia Pacific is the fastest-growing region in the cancer biomarkers market with 11.79% CAGR over the forecast period, due to an increasing cancer prevalence, increasing accessibility to healthcare, and investments in healthcare technology. Emerging economies such as China, India, and Japan are observing growth in genomics research, biomarker-based clinical trials, and personalized medicine. Also, the government-sponsored initiatives for better cancer screening programs, increasing awareness among the population, and the existence of the local biotech industry are further expected to augment the growth of the market in the region.
The cancer biomarkers market trends in Europe are growing due to its developed healthcare industry, increasing focus on precision medicine, and increasing interest in early cancer diagnosis. Advanced technology adoption Power dishes out pharma funding. Countries such as Germany, the UK, and France are also pumping more funds into R&D and innovation, driving market uptake for biomarker-based diagnostics and personalized treatment. Furthermore, favorable healthcare trends and academic-biotech partnerships are driving clinical validation and adoption of cancer biomarkers.
Latin America is experiencing significant growth in the cancer biomarkers market analysis, with an increasing and higher prevalence of cancer cases, awareness, and government support. The nation is focusing on advanced diagnostics and precision medicine in response to growing incidences of breast, prostate, and colorectal cancers. This has been driving demand for personalized medicine therapies and diagnostic tools in the region.
Middle East & Africa (MEA) is registering moderate growth in the cancer biomarkers market. Supportive national programs in countries such as Saudi Arabia, the UAE, South Africa, and Egypt, which emphasize early diagnosis and adoption of biomarkers in oncology-related infrastructure, contribute to growth. Investment in genomics and molecular diagnostics with a broader clinical capacity and research alliances is driving regional growth.
Key Players in the Cancer Biomarkers Market
Roche, Thermo Fisher Scientific, Illumina, QIAGEN, Abbott, Agilent Technologies, BD (Becton, Dickinson and Company), Bio-Rad Laboratories, Siemens Healthineers, GE Healthcare, PerkinElmer, Merck KGaA, Bristol-Myers Squibb, Pfizer, AstraZeneca, Novartis, Myriad Genetics, Exact Sciences, Foundation Medicine, Guardant Health, and other players.
Recent Developments in the Cancer Biomarkers Market
-
July 2024 – Thermo Fisher Scientific Inc., the global leader in serving science, today announced a strategic partnership with the National Cancer Institute (NCI), one of the U.S. National Institutes of Health (NIH), to fund the myeloMATCH (Molecular Analysis for Therapy Choice) precision medicine umbrella trial. This initiative will streamline research into novel treatments for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) by utilizing molecular profiling to inform treatment choices.
- August 2024 – Illumina, Inc., a global leader in DNA sequencing and array-based technologies, today announced that the U.S. Food and Drug Administration (FDA) has approved its TruSight Oncology (TSO) Comprehensive in vitro diagnostic (IVD) test. In addition to this approval, the company also gained FDA clearance for the first two companion diagnostic (CDx) indications of the test, an important milestone towards personalized oncology care.
Cancer Biomarkers Market Report Scope:
Report Attributes Details Market Size in 2024 USD 31.09 Billion Market Size by 2032 USD 72.64 Billion CAGR CAGR of 11.23% From 2025 to 2032 Base Year 2024 Forecast Period 2025-2032 Historical Data 2021-2023 Report Scope & Coverage Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook Key Segments • By Type (Breast Cancer, Prostate Cancer, Colorectal Cancer, Cervical Cancer, Liver Cancer, Lung Cancer, Others [Carcinomas, Leukemias, Lymphomas, Skin Cancers, Central Nervous System Cancers])
• By Biomolecule (Genetic Biomarkers, Epigenetic Biomarkers, Metabolic Biomarkers, Proteomic Biomarkers)
• By Application (Drug Discovery and Development, Diagnostics, Personalized Medicine)
• By Technology (Imaging Technology, OMICS)Regional Analysis/Coverage North America (US, Canada, Mexico), Europe (Germany, France, UK, Italy, Spain, Poland, Turkey, Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America) Company Profiles Roche, Thermo Fisher Scientific, Illumina, QIAGEN, Abbott, Agilent Technologies, BD (Becton, Dickinson and Company), Bio-Rad Laboratories, Siemens Healthineers, GE Healthcare, PerkinElmer, Merck KGaA, Bristol-Myers Squibb, Pfizer, AstraZeneca, Novartis, Myriad Genetics, Exact Sciences, Foundation Medicine, Guardant Health, and other players..
Table Of Contents
1. Introduction
1.1 Market Definition & Scope
1.2 Research Assumptions & Abbreviations
1.3 Research Methodology
2. Executive Summary
2.1 Market Snapshot
2.2 Market Absolute $ Opportunity Assessment & Y-o-Y Analysis, 2021–2032
2.3 Market Size & Forecast, By Segmentation, 2021–2032
2.3.1 Market Size By Type
2.3.2 Market Size By Biomolecule
2.3.3 Market Size By Biomarker Type
2.3.4 Market Size By Application
2.3.5 Market Size By Technology
2.4 Market Share & BPS Analysis By Region, 2024
2.5 Industry Growth Scenarios – Conservative, Likely & Optimistic
2.6 Industry CxO’s Perspective
3. Market Overview
3.1 Market Dynamics
3.1.1 Drivers
3.1.2 Restraints
3.1.3 Opportunities
3.1.4 Key Market Trends
3.2 Industry PESTLE Analysis
3.3 Key Industry Forces (Porter’s) Impacting Market Growth
3.4 Industry Supply Chain Analysis
3.4.1 Raw Material Suppliers
3.4.2 Manufacturers
3.4.3 Distributors/Suppliers
3.4.4 Customers/End-Users
3.5 Industry Life Cycle Assessment
3.6 Parent Market Overview
3.7 Market Risk Assessment
4. Statistical Insights & Trends Reporting
4.1 Incidence and Prevalence of Biomarker-Targeted Cancers (2024)
4.1.1 Rising global burden of cancer and its influence on biomarker demand
4.1.2 Prevalence of biomarker-linked cancers (e.g., HER2, EGFR, KRAS, BRCA)
4.1.3 Epidemiological shift toward early-stage detection via biomarkers
4.1.4 Regional variations in biomarker-relevant cancer prevalence
4.2 Biomarker-Based Prescription Trends (2024), by Region
4.2.1 Prescription trends in North America – growth in CDx usage
4.2.2 Europe’s integration of biomarker-guided therapies in clinical pathways
4.2.3 Asia-Pacific's emergence as a fast-adopting biomarker market
4.2.4 Increasing use of multi-gene panels and NGS in oncology practices
4.3 Biomarker Test Volume and Utilization, by Region (2020–2032)
4.3.1 Global test volume estimates (2020–2032) – current and forecast
4.3.2 Growth in liquid biopsy, ctDNA, and CTC testing adoption
4.3.3 Expansion of high-throughput and multiplex biomarker platforms
4.3.4 Country-wise adoption trends: U.S., Germany, Japan, China, and India
4.4 Healthcare Spending on Biomarker-Based Cancer Care, by Region (2024)
4.4.1 Government spending on biomarker diagnostics and R&D
4.4.2 Commercial investment by pharmaceutical and biotech firms
4.4.3 Private laboratory and DTC test market expenditures
4.4.4 Out-of-pocket spending trends in emerging markets
4.4.5 Reimbursement landscape evolution for companion diagnostics
5. Cancer Biomarkers Market Segmental Analysis & Forecast, By Type, 2021 – 2032,
5.1 Introduction
5.2 Breast cancer
5.2.1 Key Trends
5.2.2 Market Size & Forecast, 2021 – 2032
5.3 Prostate cancer
5.3.1 Key Trends
5.3.2 Market Size & Forecast, 2021 – 2032
5.4 Colorectal cancer
5.4.1 Key Trends
5.4.2 Market Size & Forecast, 2021 – 2032
5.5 Cervical cancer
5.5.1 Key Trends
5.5.2 Market Size & Forecast, 2021 – 2032
5.6 Liver cancer
5.6.1 Key Trends
5.6.2 Market Size & Forecast, 2021 – 2032
5.7 Lung cancer
5.7.1 Key Trends
5.7.2 Market Size & Forecast, 2021 – 2032
5.8 Others
5.8.1 Key Trends
5.8.2 Market Size & Forecast, 2021 – 2032
6. Cancer Biomarkers Market Segmental Analysis & Forecast, By Biomolecule, 2021 – 2032
6.1 Introduction
6.2 Genetic Biomarkers
6.2.1 Key Trends
6.2.2 Market Size & Forecast, 2021 – 2032
6.3 Epigenetic Biomarkers
6.3.1 Key Trends
6.3.2 Market Size & Forecast, 2021 – 2032
6.4 Metabolic Biomarkers
6.4.1 Key Trends
6.4.2 Market Size & Forecast, 2021 – 2032
6.5 Proteomic Biomarkers
6.5.1 Key Trends
6.5.2 Market Size & Forecast, 2021 – 2032
7. Cancer Biomarkers Market Segmental Analysis & Forecast, By Biomarker Type, 2021 – 2032
7.1 Introduction
7.2 PSA
7.2.1 Key Trends
7.2.2 Market Size & Forecast, 2021 – 2032
7.3 HER-2
7.3.1 Key Trends
7.3.2 Market Size & Forecast, 2021 – 2032
7.4 EGFR
7.4.1 Key Trends
7.4.2 Market Size & Forecast, 2021 – 2032
7.5 KRAS
7.5.1 Key Trends
7.5.2 Market Size & Forecast, 2021 – 2032
8. Cancer Biomarkers Market Segmental Analysis & Forecast, By Application, 2021 – 2032
8.1 Introduction
8.2 Drug discovery and Development
8.2.1 Key Trends
8.2.2 Market Size & Forecast, 2021 – 2032
8.3 Diagnostics
8.3.1 Key Trends
8.3.2 Market Size & Forecast, 2021 – 2032
8.4 Personalized medicine
8.4.1 Key Trends
8.4.2 Market Size & Forecast, 2021 – 2032
9. Cancer Biomarkers Market Segmental Analysis & Forecast, By Technology, 2021 – 2032, Value (USD Billion) & Volume (Litre)
9.1 Introduction
9.2 Imaging Technology
9.2.1 Key Trends
9.2.2 Market Size & Forecast, 2021 – 2032
9.3 OMICS
9.3.1 Key Trends
9.3.2 Market Size & Forecast, 2021 – 2032
10. Cancer Biomarkers Market Segmental Analysis & Forecast By Region, 2021 – 2032
10.1 Introduction
10.2 North America
10.2.1 Key Trends
10.2.2 Cancer Biomarkers Market Size & Forecast, By Type, 2021 – 2032
10.2.3 Cancer Biomarkers Market Size & Forecast, By Application, 2021 – 2032
10.2.4 Cancer Biomarkers Market Size & Forecast, By Biomarker Type, 2021 – 2032
10.2.5 Cancer Biomarkers Market Size & Forecast, By Biomolecule, 2021 – 2032
10.2.6 Cancer Biomarkers Market Size & Forecast, By Technology, 2021 – 2032
10.2.7 Cancer Biomarkers Market Size & Forecast, By Country, 2021 – 2032
10.2.7.1 USA
10.2.7.1.1 Cancer Biomarkers Market Size & Forecast, By Type, 2021 – 2032
10.2.7.1.2 Cancer Biomarkers Market Size & Forecast, By Application, 2021 – 2032
10.2.7.1.3 Cancer Biomarkers Market Size & Forecast, By Biomarker Type, 2021 – 2032
10.2.7.1.4 Cancer Biomarkers Market Size & Forecast, By Biomolecule, 2021 – 2032
10.2.7.1.5 Cancer Biomarkers Market Size & Forecast, By Technology, 2021 – 2032
10.2.7.2 Canada
10.2.7.2.1 Cancer Biomarkers Market Size & Forecast, By Type, 2021 – 2032
10.2.7.2.2 Cancer Biomarkers Market Size & Forecast, By Application, 2021 – 2032
10.2.7.2.3 Cancer Biomarkers Market Size & Forecast, By Biomarker Type, 2021 – 2032
10.2.7.2.4 Cancer Biomarkers Market Size & Forecast, By Biomolecule, 2021 – 2032
10.2.7.2.5 Cancer Biomarkers Market Size & Forecast, By Technology, 2021 – 2032
10.3 Europe
10.3.1 Key Trends
10.3.2 Cancer Biomarkers Market Size & Forecast, By Type, 2021 – 2032
10.3.3 Cancer Biomarkers Market Size & Forecast, By Application, 2021 – 2032
10.3.4 Cancer Biomarkers Market Size & Forecast, By Biomarker Type, 2021 – 2032
10.3.5 Cancer Biomarkers Market Size & Forecast, By Biomolecule, 2021 – 2032
10.3.6 Cancer Biomarkers Market Size & Forecast, By Technology, 2021 – 2032
10.3.7 Cancer Biomarkers Market Size & Forecast, By Country, 2021 – 2032
10.3.7.1 Germany
10.3.7.1.1 Cancer Biomarkers Market Size & Forecast, By Type, 2021 – 2032
10.3.7.1.2 Cancer Biomarkers Market Size & Forecast, By Application, 2021 – 2032
10.3.7.1.3 Cancer Biomarkers Market Size & Forecast, By Biomarker Type, 2021 – 2032
10.3.7.1.4 Cancer Biomarkers Market Size & Forecast, By Biomolecule, 2021 – 2032
10.3.7.1.5 Cancer Biomarkers Market Size & Forecast, By Technology, 2021 – 2032
10.3.7.2 UK
10.3.7.2.1 Cancer Biomarkers Market Size & Forecast, By Type, 2021 – 2032
10.3.7.2.2 Cancer Biomarkers Market Size & Forecast, By Application, 2021 – 2032
10.3.7.2.3 Cancer Biomarkers Market Size & Forecast, By Biomarker Type, 2021 – 2032
10.3.7.2.4 Cancer Biomarkers Market Size & Forecast, By Biomolecule, 2021 – 2032
10.3.7.2.5 Cancer Biomarkers Market Size & Forecast, By Technology, 2021 – 2032
10.3.7.3 France
10.3.7.3.1 Cancer Biomarkers Market Size & Forecast, By Type, 2021 – 2032
10.3.7.3.2 Cancer Biomarkers Market Size & Forecast, By Application, 2021 – 2032
10.3.7.3.3 Cancer Biomarkers Market Size & Forecast, By Biomarker Type, 2021 – 2032
10.3.7.3.4 Cancer Biomarkers Market Size & Forecast, By Biomolecule, 2021 – 2032
10.3.7.3.5 Cancer Biomarkers Market Size & Forecast, By Technology, 2021 – 2032
10.3.7.4 Italy
10.3.7.4.1 Cancer Biomarkers Market Size & Forecast, By Type, 2021 – 2032
10.3.7.4.2 Cancer Biomarkers Market Size & Forecast, By Application, 2021 – 2032
10.3.7.4.3 Cancer Biomarkers Market Size & Forecast, By Biomarker Type, 2021 – 2032
10.3.7.4.4 Cancer Biomarkers Market Size & Forecast, By Biomolecule, 2021 – 2032
10.3.7.4.5 Cancer Biomarkers Market Size & Forecast, By Technology, 2021 – 2032
10.3.7.5 Spain
10.3.7.5.1 Cancer Biomarkers Market Size & Forecast, By Type, 2021 – 2032
10.3.7.5.2 Cancer Biomarkers Market Size & Forecast, By Application, 2021 – 2032
10.3.7.5.3 Cancer Biomarkers Market Size & Forecast, By Biomarker Type, 2021 – 2032
10.3.7.5.4 Cancer Biomarkers Market Size & Forecast, By Biomolecule, 2021 – 2032
10.3.7.5.5 Cancer Biomarkers Market Size & Forecast, By Technology, 2021 – 2032
10.3.7.6 Russia
10.3.7.6.1 Cancer Biomarkers Market Size & Forecast, By Type, 2021 – 2032
10.3.7.6.2 Cancer Biomarkers Market Size & Forecast, By Application, 2021 – 2032
10.3.7.6.3 Cancer Biomarkers Market Size & Forecast, By Biomarker Type, 2021 – 2032
10.3.7.6.4 Cancer Biomarkers Market Size & Forecast, By Biomolecule, 2021 – 2032
10.3.7.6.5 Cancer Biomarkers Market Size & Forecast, By Technology, 2021 – 2032
10.3.7.7 Poland
10.3.7.7.1 Cancer Biomarkers Market Size & Forecast, By Type, 2021 – 2032
10.3.7.7.2 Cancer Biomarkers Market Size & Forecast, By Application, 2021 – 2032
10.3.7.7.3 Cancer Biomarkers Market Size & Forecast, By Biomarker Type, 2021 – 2032
10.3.7.7.4 Cancer Biomarkers Market Size & Forecast, By Biomolecule, 2021 – 2032
10.3.7.7.5 Cancer Biomarkers Market Size & Forecast, By Technology, 2021 – 2032
10.3.7.8 Rest of Europe
10.3.7.8.1 Cancer Biomarkers Market Size & Forecast, By Type, 2021 – 2032
10.3.7.8.2 Cancer Biomarkers Market Size & Forecast, By Application, 2021 – 2032
10.3.7.8.3 Cancer Biomarkers Market Size & Forecast, By Biomarker Type, 2021 – 2032
10.3.7.8.4 Cancer Biomarkers Market Size & Forecast, By Biomolecule, 2021 – 2032
10.3.7.8.5 Cancer Biomarkers Market Size & Forecast, By Technology, 2021 – 2032
10.4 Asia-Pacific
10.4.1 Key Trends
10.4.2 Cancer Biomarkers Market Size & Forecast, By Type, 2021 – 2032
10.4.3 Cancer Biomarkers Market Size & Forecast, By Application, 2021 – 2032
10.4.4 Cancer Biomarkers Market Size & Forecast, By Biomarker Type, 2021 – 2032
10.4.5 Cancer Biomarkers Market Size & Forecast, By Biomolecule, 2021 – 2032
10.4.6 Cancer Biomarkers Market Size & Forecast, By Technology, 2021 – 2032
10.4.7 Cancer Biomarkers Market Size & Forecast, By Country, 2021 – 2032
10.4.7.1 China
10.4.7.1.1 Cancer Biomarkers Market Size & Forecast, By Type, 2021 – 2032
10.4.7.1.2 Cancer Biomarkers Market Size & Forecast, By Application, 2021 – 2032
10.4.7.1.3 Cancer Biomarkers Market Size & Forecast, By Biomarker Type, 2021 – 2032
10.4.7.1.4 Cancer Biomarkers Market Size & Forecast, By Biomolecule, 2021 – 2032
10.4.7.1.5 Cancer Biomarkers Market Size & Forecast, By Technology, 2021 – 2032
10.4.7.2 India
10.4.7.2.1 Cancer Biomarkers Market Size & Forecast, By Type, 2021 – 2032
10.4.7.2.2 Cancer Biomarkers Market Size & Forecast, By Application, 2021 – 2032
10.4.7.2.3 Cancer Biomarkers Market Size & Forecast, By Biomarker Type, 2021 – 2032
10.4.7.2.4 Cancer Biomarkers Market Size & Forecast, By Biomolecule, 2021 – 2032
10.4.7.2.5 Cancer Biomarkers Market Size & Forecast, By Technology, 2021 – 2032
10.4.7.3 Japan
10.4.7.3.1 Cancer Biomarkers Market Size & Forecast, By Type, 2021 – 2032
10.4.7.3.2 Cancer Biomarkers Market Size & Forecast, By Application, 2021 – 2032
10.4.7.3.3 Cancer Biomarkers Market Size & Forecast, By Biomarker Type, 2021 – 2032
10.4.7.3.4 Cancer Biomarkers Market Size & Forecast, By Biomolecule, 2021 – 2032
10.4.7.3.5 Cancer Biomarkers Market Size & Forecast, By Technology, 2021 – 2032
10.4.7.4 South Korea
10.4.7.4.1 Cancer Biomarkers Market Size & Forecast, By Type, 2021 – 2032
10.4.7.4.2 Cancer Biomarkers Market Size & Forecast, By Application, 2021 – 2032
10.4.7.4.3 Cancer Biomarkers Market Size & Forecast, By Biomarker Type, 2021 – 2032
10.4.7.4.4 Cancer Biomarkers Market Size & Forecast, By Biomolecule, 2021 – 2032
10.4.7.4.5 Cancer Biomarkers Market Size & Forecast, By Technology, 2021 – 2032
10.4.7.5 Australia
10.4.7.5.1 Cancer Biomarkers Market Size & Forecast, By Type, 2021 – 2032
10.4.7.5.2 Cancer Biomarkers Market Size & Forecast, By Application, 2021 – 2032
10.4.7.5.3 Cancer Biomarkers Market Size & Forecast, By Biomarker Type, 2021 – 2032
10.4.7.5.4 Cancer Biomarkers Market Size & Forecast, By Biomolecule, 2021 – 2032
10.4.7.5.5 Cancer Biomarkers Market Size & Forecast, By Technology, 2021 – 2032
10.4.7.6 ASEAN Countries
10.4.7.6.1 Cancer Biomarkers Market Size & Forecast, By Type, 2021 – 2032
10.4.7.6.2 Cancer Biomarkers Market Size & Forecast, By Application, 2021 – 2032
10.4.7.6.3 Cancer Biomarkers Market Size & Forecast, By Biomarker Type, 2021 – 2032
10.4.7.6.4 Cancer Biomarkers Market Size & Forecast, By Biomolecule, 2021 – 2032
10.4.7.6.5 Cancer Biomarkers Market Size & Forecast, By Technology, 2021 – 2032
10.4.7.7 Rest of Asia-Pacific
10.4.7.7.1 Cancer Biomarkers Market Size & Forecast, By Type, 2021 – 2032
10.4.7.7.2 Cancer Biomarkers Market Size & Forecast, By Application, 2021 – 2032
10.4.7.7.3 Cancer Biomarkers Market Size & Forecast, By Biomarker Type, 2021 – 2032
10.4.7.7.4 Cancer Biomarkers Market Size & Forecast, By Biomolecule, 2021 – 2032
10.4.7.7.5 Cancer Biomarkers Market Size & Forecast, By Technology, 2021 – 2032
10.5 Latin America
10.5.1 Key Trends
10.5.2 Cancer Biomarkers Market Size & Forecast, By Type, 2021 – 2032
10.5.3 Cancer Biomarkers Market Size & Forecast, By Application, 2021 – 2032
10.5.4 Cancer Biomarkers Market Size & Forecast, By Biomarker Type, 2021 – 2032
10.5.5 Cancer Biomarkers Market Size & Forecast, By Biomolecule, 2021 – 2032
10.5.6 Cancer Biomarkers Market Size & Forecast, By Technology, 2021 – 2032
10.5.7 Cancer Biomarkers Market Size & Forecast, By Country, 2021 – 2032
10.5.7.1 Brazil
10.5.7.1.1 Cancer Biomarkers Market Size & Forecast, By Type, 2021 – 2032
10.5.7.1.2 Cancer Biomarkers Market Size & Forecast, By Application, 2021 – 2032
10.5.7.1.3 Cancer Biomarkers Market Size & Forecast, By Biomarker Type, 2021 – 2032
10.5.7.1.4 Cancer Biomarkers Market Size & Forecast, By Biomolecule, 2021 – 2032
10.5.7.1.5 Cancer Biomarkers Market Size & Forecast, By Technology, 2021 – 2032
10.5.7.2 Argentina
10.5.7.2.1 Cancer Biomarkers Market Size & Forecast, By Type, 2021 – 2032
10.5.7.2.2 Cancer Biomarkers Market Size & Forecast, By Application, 2021 – 2032
10.5.7.2.3 Cancer Biomarkers Market Size & Forecast, By Biomarker Type, 2021 – 2032
10.5.7.2.4 Cancer Biomarkers Market Size & Forecast, By Biomolecule, 2021 – 2032
10.5.7.2.5 Cancer Biomarkers Market Size & Forecast, By Technology, 2021 – 2032
10.5.7.3 Mexico
10.5.7.3.1 Cancer Biomarkers Market Size & Forecast, By Type, 2021 – 2032
10.5.7.3.2 Cancer Biomarkers Market Size & Forecast, By Application, 2021 – 2032
10.5.7.3.3 Cancer Biomarkers Market Size & Forecast, By Biomarker Type, 2021 – 2032
10.5.7.3.4 Cancer Biomarkers Market Size & Forecast, By Biomolecule, 2021 – 2032
10.5.7.3.5 Cancer Biomarkers Market Size & Forecast, By Technology, 2021 – 2032
10.5.7.4 Colombia
10.5.7.4.1 Cancer Biomarkers Market Size & Forecast, By Type, 2021 – 2032
10.5.7.4.2 Cancer Biomarkers Market Size & Forecast, By Application, 2021 – 2032
10.5.7.4.3 Cancer Biomarkers Market Size & Forecast, By Biomarker Type, 2021 – 2032
10.5.7.4.4 Cancer Biomarkers Market Size & Forecast, By Biomolecule, 2021 – 2032
10.5.7.4.5 Cancer Biomarkers Market Size & Forecast, By Technology, 2021 – 2032
10.5.7.5 Rest of Latin America
10.5.7.5.1 Cancer Biomarkers Market Size & Forecast, By Type, 2021 – 2032
10.5.7.5.2 Cancer Biomarkers Market Size & Forecast, By Application, 2021 – 2032
10.5.7.5.3 Cancer Biomarkers Market Size & Forecast, By Biomarker Type, 2021 – 2032
10.5.7.5.4 Cancer Biomarkers Market Size & Forecast, By Biomolecule, 2021 – 2032
10.5.7.5.5 Cancer Biomarkers Market Size & Forecast, By Technology, 2021 – 2032
10.6 Middle East & Africa
10.6.1 Key Trends
10.6.2 Cancer Biomarkers Market Size & Forecast, By Type, 2021 – 2032
10.6.3 Cancer Biomarkers Market Size & Forecast, By Application, 2021 – 2032
10.6.4 Cancer Biomarkers Market Size & Forecast, By Biomarker Type, 2021 – 2032
10.6.5 Cancer Biomarkers Market Size & Forecast, By Biomolecule, 2021 – 2032
10.6.6 Cancer Biomarkers Market Size & Forecast, By Technology, 2021 – 2032
10.6.7 Cancer Biomarkers Market Size & Forecast, By Country, 2021 – 2032
10.6.7.1 UAE
10.6.7.1.1 Cancer Biomarkers Market Size & Forecast, By Type, 2021 – 2032
10.6.7.1.2 Cancer Biomarkers Market Size & Forecast, By Application, 2021 – 2032
10.6.7.1.3 Cancer Biomarkers Market Size & Forecast, By Biomarker Type, 2021 – 2032
10.6.7.1.4 Cancer Biomarkers Market Size & Forecast, By Biomolecule, 2021 – 2032
10.6.7.1.5 Cancer Biomarkers Market Size & Forecast, By Technology, 2021 – 2032
10.6.7.2 Saudi Arabia
10.6.7.2.1 Cancer Biomarkers Market Size & Forecast, By Type, 2021 – 2032
10.6.7.2.2 Cancer Biomarkers Market Size & Forecast, By Application, 2021 – 2032
10.6.7.2.3 Cancer Biomarkers Market Size & Forecast, By Biomarker Type, 2021 – 2032
10.6.7.2.4 Cancer Biomarkers Market Size & Forecast, By Biomolecule, 2021 – 2032
10.6.7.2.5 Cancer Biomarkers Market Size & Forecast, By Technology, 2021 – 2032
10.6.7.3 Qatar
10.6.7.3.1 Cancer Biomarkers Market Size & Forecast, By Type, 2021 – 2032
10.6.7.3.2 Cancer Biomarkers Market Size & Forecast, By Application, 2021 – 2032
10.6.7.3.3 Cancer Biomarkers Market Size & Forecast, By Biomarker Type, 2021 – 2032
10.6.7.3.4 Cancer Biomarkers Market Size & Forecast, By Biomolecule, 2021 – 2032
10.6.7.3.5 Cancer Biomarkers Market Size & Forecast, By Technology, 2021 – 2032
10.6.7.4 Egypt
10.6.7.4.1 Cancer Biomarkers Market Size & Forecast, By Type, 2021 – 2032
10.6.7.4.2 Cancer Biomarkers Market Size & Forecast, By Application, 2021 – 2032
10.6.7.4.3 Cancer Biomarkers Market Size & Forecast, By Biomarker Type, 2021 – 2032
10.6.7.4.4 Cancer Biomarkers Market Size & Forecast, By Biomolecule, 2021 – 2032
10.6.7.4.5 Cancer Biomarkers Market Size & Forecast, By Technology, 2021 – 2032
10.6.7.5 South Africa
10.6.7.5.1 Cancer Biomarkers Market Size & Forecast, By Type, 2021 – 2032
10.6.7.5.2 Cancer Biomarkers Market Size & Forecast, By Application, 2021 – 2032
10.6.7.5.3 Cancer Biomarkers Market Size & Forecast, By Biomarker Type, 2021 – 2032
10.6.7.5.4 Cancer Biomarkers Market Size & Forecast, By Biomolecule, 2021 – 2032
10.6.7.5.5 Cancer Biomarkers Market Size & Forecast, By Technology, 2021 – 2032
10.6.7.6 Rest of Middle East & Africa
10.6.7.6.1 Cancer Biomarkers Market Size & Forecast, By Type, 2021 – 2032
10.6.7.6.2 Cancer Biomarkers Market Size & Forecast, By Application, 2021 – 2032
10.6.7.6.3 Cancer Biomarkers Market Size & Forecast, By Biomarker Type, 2021 – 2032
10.6.7.6.4 Cancer Biomarkers Market Size & Forecast, By Biomolecule, 2021 – 2032
10.6.7.6.5 Cancer Biomarkers Market Size & Forecast, By Technology, 2021 – 2032
11. Competitive Landscape
11.1 Key Players' Positioning
11.2 Competitive Developments
11.2.1 Key Strategies Adopted (%), By Key Players, 2024
11.2.2 Year-Wise Strategies & Development, 2021 – 2025
11.2.3 Number Of Strategies Adopted By Key Players, 2024
11.3 Market Share Analysis, 2024
11.4 Product/Service & Application Benchmarking
11.4.1 Product/Service Specifications & Features By Key Players
11.4.2 Product/Service Heatmap By Key Players
11.4.3 Application Heatmap By Key Players
11.5 Industry Start-Up & Innovation Landscape
11.6 Key Company Profiles
11.6 Key Company Profiles
11.6.1 Roche
11.6.1.1 Company Overview & Snapshot
11.6.1.2 Product/Service Portfolio
11.6.1.3 Key Company Financials
11.6.1.4 SWOT Analysis
11.6.2 Thermo Fisher Scientific
11.6.2.1 Company Overview & Snapshot
11.6.2.2 Product/Service Portfolio
11.6.2.3 Key Company Financials
11.6.2.4 SWOT Analysis
11.6.3 Illumina
11.6.3.1 Company Overview & Snapshot
11.6.3.2 Product/Service Portfolio
11.6.3.3 Key Company Financials
11.6.3.4 SWOT Analysis
11.6.4 QIAGEN
11.6.4.1 Company Overview & Snapshot
11.6.4.2 Product/Service Portfolio
11.6.4.3 Key Company Financials
11.6.4.4 SWOT Analysis
11.6.5 Abbott
11.6.5.1 Company Overview & Snapshot
11.6.5.2 Product/Service Portfolio
11.6.5.3 Key Company Financials
11.6.5.4 SWOT Analysis
11.6.6 Agilent Technologies
11.6.6.1 Company Overview & Snapshot
11.6.6.2 Product/Service Portfolio
11.6.6.3 Key Company Financials
11.6.6.4 SWOT Analysis
11.6.7 BD (Becton, Dickinson and Company)
11.6.7.1 Company Overview & Snapshot
11.6.7.2 Product/Service Portfolio
11.6.7.3 Key Company Financials
11.6.7.4 SWOT Analysis
11.6.8 Bio-Rad Laboratories
11.6.8.1 Company Overview & Snapshot
11.6.8.2 Product/Service Portfolio
11.6.8.3 Key Company Financials
11.6.8.4 SWOT Analysis
11.6.9 Siemens Healthineers
11.6.9.1 Company Overview & Snapshot
11.6.9.2 Product/Service Portfolio
11.6.9.3 Key Company Financials
11.6.9.4 SWOT Analysis
11.6.10 GE Healthcare
11.6.10.1 Company Overview & Snapshot
11.6.10.2 Product/Service Portfolio
11.6.10.3 Key Company Financials
11.6.10.4 SWOT Analysis
11.6.11 PerkinElmer
11.6.11.1 Company Overview & Snapshot
11.6.11.2 Product/Service Portfolio
11.6.11.3 Key Company Financials
11.6.11.4 SWOT Analysis
11.6.12 Merck KGaA
11.6.12.1 Company Overview & Snapshot
11.6.12.2 Product/Service Portfolio
11.6.12.3 Key Company Financials
11.6.12.4 SWOT Analysis
11.6.13 Bristol-Myers Squibb
11.6.13.1 Company Overview & Snapshot
11.6.13.2 Product/Service Portfolio
11.6.13.3 Key Company Financials
11.6.13.4 SWOT Analysis
11.6.14 Pfizer
11.6.14.1 Company Overview & Snapshot
11.6.14.2 Product/Service Portfolio
11.6.14.3 Key Company Financials
11.6.14.4 SWOT Analysis
11.6.15 AstraZeneca
11.6.15.1 Company Overview & Snapshot
11.6.15.2 Product/Service Portfolio
11.6.15.3 Key Company Financials
11.6.15.4 SWOT Analysis
11.6.16 Novartis
11.6.16.1 Company Overview & Snapshot
11.6.16.2 Product/Service Portfolio
11.6.16.3 Key Company Financials
11.6.16.4 SWOT Analysis
11.6.17 Myriad Genetics
11.6.17.1 Company Overview & Snapshot
11.6.17.2 Product/Service Portfolio
11.6.17.3 Key Company Financials
11.6.17.4 SWOT Analysis
11.6.18 Exact Sciences
11.6.18.1 Company Overview & Snapshot
11.6.18.2 Product/Service Portfolio
11.6.18.3 Key Company Financials
11.6.18.4 SWOT Analysis
11.6.19 Foundation Medicine
11.6.19.1 Company Overview & Snapshot
11.6.19.2 Product/Service Portfolio
11.6.19.3 Key Company Financials
11.6.19.4 SWOT Analysis
11.6.20 Guardant Health
11.6.20.1 Company Overview & Snapshot
11.6.20.2 Product/Service Portfolio
11.6.20.3 Key Company Financials
11.6.20.4 SWOT Analysis
12. Analyst Recommendations
12.1 SNS Insider Opportunity Map
12.2 Industry Low-Hanging Fruit Assessment
12.3 Market Entry & Growth Strategy
12.4 Analyst Viewpoint & Suggestions On Market Growth
13. Assumptions
14. Disclaimer
15. Appendix
15.1 List Of Tables
15.2 List Of Figures
Key Market Segments:
By Type
-
- Breast cancer
- Prostate cancer
- Colorectal cancer
- Cervical cancer
- Liver cancer
- Lung cancer
- Others (Carcinomas, Leukemias, Lymphomas, Skin Cancers, Central Nervous System Cancers)
By Biomolecule
-
- Genetic Biomarkers
- Epigenetic Biomarkers
- Metabolic Biomarkers
- Proteomic Biomarkers
By Biomarker Type
- PSA
- HER-2
- EGFR
- KRAS
By Application
-
- Drug discovery and Development
- Diagnostics
- Personalized medicine
By Technology
-
- Imaging Technology
- OMICS
Request for Segment Customization as per your Business Requirement: https://www.snsinsider.com/sample-request/3324
Regional Coverage:
North America
- US
- Canada
- Mexico
Europe
- Germany
- France
- UK
- Italy
- Spain
- Poland
- Turkey
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Singapore
- Australia
- Rest of Asia Pacific
Middle East & Africa
- UAE
- Saudi Arabia
- Qatar
- South Africa
- Rest of Middle East & Africa
Latin America
- Brazil
- Argentina
- Rest of Latin America
Request for Country Level Research Report: https://www.snsinsider.com/sample-request/3324
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
- Detailed Volume Analysis
- Criss-Cross segment analysis (e.g., Product X Application)
- Competitive Product Benchmarking
- Geographic Analysis
- Additional countries in any of the regions
- Customized Data Representation
- Detailed analysis and profiling of additional market players
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
